8-K: Denali Therapeutics Initiates BLA Filing for Tividenofusp Alfa in Hunter Syndrome Treatment

Denali Therapeutics has begun a rolling submission of a biologics license application (BLA) to the FDA for tividenofusp alfa, aimed at treating Hunter syndrome (MPS II), with potential U.S. commercial launch anticipated in late 2025 or early 2026.

Summary

• Denali Therapeutics has initiated a rolling submission of a Biologics License Application (BLA) for tividenofusp alfa to treat Hunter syndrome (MPS II).
• The BLA is for accelerated approval, supported by cerebrospinal fluid heparan sulfate (CSF HS) as a surrogate endpoint.
• Denali expects to complete the BLA submission in the first half of May 2025.
• The company is preparing for a potential U.S. commercial launch in late 2025 or early 2026.
• Denali is also collaborating with the FDA through the START program for an accelerated development and approval path for DNL126 for Sanfilippo syndrome.
• Tividenofusp alfa has received Fast Track and Breakthrough Therapy designations from the FDA and Priority Medicines designation from the European Medicines Agency.
• The Phase 2/3 COMPASS study is enrolling participants with MPS II in North America, South America, and Europe.
• Denali is conducting a Phase 1/2 study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory clinical efficacy of DNL126 in participants with MPS IIIA.

Sentiment

Score: 8

Explanation: The announcement is positive due to the progress in regulatory submissions and potential commercial launch, indicating advancement in Denali's pipeline and potential revenue generation.

Positives

• Initiation of BLA filing for tividenofusp alfa represents a significant regulatory milestone.
• Alignment with the FDA on the BLA data package, including the use of CSF HS as a surrogate endpoint, is a positive sign.
• Fast Track and Breakthrough Therapy designations from the FDA and Priority Medicines designation from the EMA could expedite the approval process.
• Ongoing collaboration with the FDA through the START program for DNL126 is promising.
• Potential commercial launch in late 2025 or early 2026 could provide a new treatment option for Hunter syndrome patients.

Risks

• The BLA is for accelerated approval, which may require further studies for full approval.
• Commercial launch is subject to regulatory approval and market conditions.
• Clinical trials may face challenges in patient enrollment.
• Reliance on third-party manufacturers and suppliers could pose risks.
• The safety and efficacy profiles of Denali's product candidates have not yet been fully established.

Future Outlook

Denali anticipates completing the BLA submission in the first half of May 2025 and is preparing for a potential U.S. commercial launch in late 2025 or early 2026.

Management Comments

• 'We are grateful to the FDA for their ongoing support of our BLA filing and continued dedication to advance new medicines,' said Carole Ho, M.D., Chief Medical Officer of Denali.
• She added that this regulatory milestone brings them closer to delivering a new treatment option to the Hunter syndrome community and supports the expansion of their Enzyme TransportVehicle franchise.

Industry Context

This announcement positions Denali Therapeutics as a key player in the development of treatments for rare genetic diseases, specifically Hunter syndrome and Sanfilippo syndrome, addressing unmet needs in these patient communities.

Comparison to Industry Standards

• Enzyme replacement therapy is the current standard of care for Hunter Syndrome, but it does not cross the blood-brain barrier, leaving cognitive and behavioral symptoms unaddressed.
• Tividenofusp alfa is designed to cross the blood-brain barrier, potentially offering a more comprehensive treatment approach compared to existing therapies.
• Other companies like BioMarin Pharmaceutical have therapies for MPS disorders, but Denali's Enzyme Transport Vehicle technology aims to improve drug delivery to the brain, a key differentiator.

Stakeholder Impact

• Positive impact on Hunter syndrome patients and their families by potentially providing a new treatment option.
• Positive impact on shareholders due to the advancement of Denali's pipeline.
• Potential positive impact on employees through company growth and development.

Next Steps

• Complete the BLA submission in the first half of May 2025.
• Continue enrollment in the Phase 2/3 COMPASS study.
• Continue the Phase 1/2 study of DNL126.
• Prepare for potential U.S. commercial launch in late 2025 or early 2026, pending regulatory approval.

Key Dates

Keywords

tividenofusp alfa, Hunter syndrome, MPS II, DNL126, Sanfilippo syndrome, MPS IIIA, BLA, FDA, Denali Therapeutics, Enzyme TransportVehicle, accelerated approval, neuordegenerative diseases, lysosomal storage diseases